ArticleAmbio2026
A golden opportunity: Corporate sustainability reporting as a key lever to address nature-related risks.
Article in Ambio, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Corporate sustainability reporting currently fails to provide the information needed for companies, their investors and society to address mounting environmental risks because predominant reporting requirements focus heavily on firm-level risks, neglecting cumulative impacts on climate and nature. Recently, sustainability reporting has also been critiqued for the administrative burden it places on companies. Corporate reporting may seem far removed from sustainability science but is, in fact, a critical lever in directing corporate practice. A golden opportunity therefore exists for sustainability science to simultaneously help reduce, refine and improve sustainability reporting by identifying the most prioritized mandatory environmental disclosures and support the development of an open-access disclosure repository. This would radically improve the ability of investors, regulators, and public agencies to appraise environmental pressures, improve corporate accountability, and mitigate growing systemic risks. Treating environmental data with the rigor granted to financial data is fundamental to align capital with sustainability objectives.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.